Intelligent Bio Solutions Validates Fingerprint Sweat Testing for Drug Detection with Pharmacokinetic Study Data
核心洞察
Intelligent Bio Solutions' pharmacokinetic study demonstrates that fingerprint sweat mirrors the rate and extent of codeine found in blood and saliva, establishing it as a strong indicator of drug ingestion.
Statistical comparisons at the 95% confidence level showed that fingerprint sweat provides a reliable sample matrix for drug detection, with quantitative pharmacokinetic data closely aligning with blood-based results.
The company will present these findings at the ADLM 2025 Clinical Lab Expo, reinforcing the viability of their non-invasive Intelligent Fingerprinting Drug Screening System for diagnostic testing.
Intelligent Bio Solutions Inc. has validated the clinical utility of fingerprint sweat testing for drug detection through a comprehensive pharmacokinetic study, positioning the company's non-invasive screening technology as a viable alternative to traditional blood and saliva testing methods. The medical technology company will present these findings at the Association for Diagnostics and Laboratory Medicine (搜索) (ADLM) 2025 Clinical Lab Expo in Chicago from July 27-31.
Pharmacokinetic Study Validates Fingerprint Sweat as Reliable Drug Detection Matrix
The pharmacokinetic study collected human fingerprint sweat specimens for laboratory analysis using INBS's Intelligent Fingerprinting Drug Screening System, a portable device that screens for drugs of abuse via sweat from fingertips. Study data revealed that fingerprint sweat mirrors the rate and extent of codeine found in blood and saliva, establishing it as a strong indicator of codeine ingestion.
Statistical comparisons conducted at the 95% confidence level demonstrated that fingerprint sweat provides a reliable sample matrix for drug detection, with quantitative pharmacokinetic data closely aligning with blood-based results. This validation addresses a critical need for non-invasive diagnostic testing methods that maintain clinical accuracy while improving patient comfort and reducing biohazard risks.
"ADLM is an important gathering for laboratory medicine professionals, and we're pleased to share data showing that fingerprint sweat specimens reflect the recent ingestion of codeine," said Daniel Brown, Head of Clinical Affairs at Intelligent Bio Solutions. "This reinforces that our system of fingerprint sweat testing is a viable option for non-invasive diagnostic testing. We see growing demand for innovative drug screening approaches that are simple to administer, minimize biohazard risks, and offer reliable, rapid results."
Technology Specifications and Clinical Applications
The Intelligent Fingerprinting Drug Screening System is designed as a hygienic and cost-effective solution that screens for recent use of drugs commonly found in workplace settings, including opiates (搜索), cocaine, methamphetamine, and cannabis. The technology enables sample collection in seconds with results delivered in under ten minutes, making it particularly valuable for employers in safety-critical industries.
The system supports accurate, dignified, and efficient testing across workplace, treatment, and justice settings. With more than 450 accounts across 24 countries, INBS continues to expand its reach across numerous sectors, including construction, transportation, engineering, mining, and manufacturing.
ADLM 2025 Presentation and Industry Impact
Daniel Brown will represent the company at ADLM 2025, participating in the Poster Hall forum featuring more than 700 presentations spanning laboratory medicine. He will present the background, methodology, and findings of the company's recent pharmacokinetic study and will be available during discussion periods to engage directly with attendees.
ADLM 2025 serves as the world's premier global laboratory medicine exposition, bringing together international leaders, scientists, and innovators. The event features over 300 expert speakers, more than 250 educational sessions, and 200-plus product categories, offering a platform to explore advances in diagnostic technologies and clinical laboratory innovation.
The company's participation in ADLM 2025 highlights its commitment to innovation and growing relevance within laboratory and diagnostic testing communities. Attendees will have opportunities to learn about INBS's technology, explore real-world applications, and discuss collaboration and adoption opportunities with company representatives.